ARRY: Array Technologies, Inc. Stock

by  •  • Comments Off on ARRY: Array Technologies, Inc. Stock

SIC 399 – Miscellaneous Manufacturing Industries

Valuation
Market Cap ($M) 970.16
Enterprise Value ($M) 1,706.75
Book Value ($M) 457.08
Book Value / Share 3.01
Price / Book 2.12
NCAV ($M) -203.74
NCAV / Share -1.34
Price / NCAV -4.76

Profitability (mra)
Return on Invested Capital (ROIC) -0.08
Return on Assets (ROA) -0.06
Return on Equity (ROE) -0.15

Liquidity (mrq)
Quick Ratio 1.88
Current Ratio 2.41

Balance Sheet (mrq) ($M)
Current Assets 902.28
Assets 1,563.10
Liabilities 1,106.03
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-13 SCHEDULE 13G Point72 Asset Management, L.P.
11-14 13G/A Electron Capital Partners, LLC 1.20 -76.95
11-13 13G Grantham, Mayo, Van Otterloo & Co. LLC 5.35
11-12 13G/A BlackRock, Inc. 10.10 0.00
11-12 13G Goldman Sachs Group Inc 5.60
11-12 13G/A Hill City Capital, LP 9.39 61.37
02-13 13G/A Vanguard Group Inc 9.18 0.32
02-09 13G/A Fmr Llc 1.73 -67.42

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-23 881,683 3,763,086 23.43
2025-01-22 1,473,079 5,467,344 26.94
2025-01-21 1,547,705 6,411,907 24.14

(click for more detail)


Financial data and stock pages provided by
Fintel.io

Finpedia: Array BioPharma